AMENDMENT NO. 1 TO COLLABORATION AND LICENSE AGREEMENTCollaboration and License Agreement • June 26th, 2013 • Regulus Therapeutics Inc. • Pharmaceutical preparations • New York
This Amendment No. 1 to Collaboration and License Agreement (this “Amendment”) dated June 24, 2013, is by and between Regulus Therapeutics Inc., a Delaware corporation with its principal address at 3545 John Hopkins Ct., Suite 210, San Diego, CA 92121 (“Regulus”), and Biogen Idec MA Inc., a Massachusetts corporation with its principal address at 133 Boston Post Road, Weston, MA 02493 (“BI”). Regulus and BI may each be referred to herein individually as a “Party” and collectively as the “Parties.”
AMENDMENT #5 TO THE PRODUCT DEVELOPMENT AND COMMERCIALIZATION AGREEMENTProduct Development and Commercialization Agreement • June 26th, 2013 • Regulus Therapeutics Inc. • Pharmaceutical preparations
This Amendment (this “Amendment”) is entered into and made effective as of June 6, 2013 (the “Amendment Date”) by and between Regulus Therapeutics Inc., a Delaware corporation having its principal place of business at 3545 John Hopkins Court, Suite 210, San Diego, CA 92121 USA (“Regulus”) and Glaxo Group Limited, a company existing under the laws of England and Wales, having its registered office at 980 Great West Road, Brentford, Middlesex TW8 9GS, England (“GSK”).
AMENDMENT Nr.1 (to Collaboration and License Agreement)Collaboration and License Agreement • June 26th, 2013 • Regulus Therapeutics Inc. • Pharmaceutical preparations
REGULUS THERAPEUTICS INC., a Delaware Corporation (“Regulus”) having a place of business at 3545 John Hopkins Court, San Diego, California 92121-1121, U.S.A.
April 26, 2013 Sanofi 54, rue La Boétie, 75414 Paris, France Attn: Philippe Goupit, Vice President, Corporate Licenses, Strategy & Development Dear Philippe: Amended and Restated Collaboration and License Agreement between Sanofi and Regulus...Regulus Therapeutics Inc. • June 26th, 2013 • Pharmaceutical preparations
Sanofi and Regulus Therapeutics, Inc. (“Regulus”) are parties to that certain Amended and Restated Collaboration and License Agreement, effective as of July 16, 2012 (the “Agreement”) and as amended February 25, 2013.
] Shares REGULUS THERAPEUTICS INC. COMMON STOCK, PAR VALUE $0.001 PER SHARE UNDERWRITING AGREEMENTUnderwriting Agreement • June 26th, 2013 • Regulus Therapeutics Inc. • Pharmaceutical preparations • New York
INTRODUCTION. Regulus Therapeutics Inc., a Delaware corporation (the “Company”), proposes to issue and sell to the several Underwriters named in Schedule I hereto (the “Underwriters”) an aggregate of [ ] shares (the “Firm Shares”) of the common stock, $0.001 par value per share (the “Common Stock”), of the Company.
